Category: news&events

Halle (Saale), 2. August 2023. Icon Genet­ics GmbH, a whol­ly owned sub­sidiary of Den­ka Co. Ltd, Tokyo, Japan, announced today that it has been grant­ed a Euro­pean patent (EP3938378B1) for its inven­tion on norovirus-like par­ti­cles with improved sta­bil­i­ty. The patent appli­ca­tion was filed on 11. March 2020 and grant­ed on 2. August 2023. The inven­tion… Read more »

Halle (Saale), 26 June 2023. Icon Genet­ics GmbH, a whol­ly owned sub­sidiary of Den­ka Co. Ltd, Tokyo, Japan, has pub­lished a sec­ond mile­stone paper in the renowned jour­nal “Fron­tiers in Immunol­o­gy” detail­ing on the remark­able immune respons­es elicit­ed by its norovirus vac­cine can­di­date dur­ing the suc­cess­ful­ly com­plet­ed Phase I clin­i­cal study.   Norovirus­es are respon­si­ble… Read more »

Halle (Saale), 07. Octo­ber 2022. Icon Genet­ics GmbH, a whol­ly owned sub­sidiary of Den­ka Co. Ltd, Tokyo, Japan, has suc­cess­ful­ly com­plet­ed a Phase I clin­i­cal study of its norovirus vac­cine can­di­date and pub­lished a first mile­stone paper in the renowned jour­nal “Fron­tiers in Immunol­o­gy”. Norovirus­es are respon­si­ble for approx­i­mate­ly 20% of all cas­es of acute… Read more »

Halle (Saale), 11. Feb­ru­ary 2022. Icon Genet­ics GmbH, a whol­ly owned sub­sidiary of Den­ka Co. Ltd, Tokyo, Japan, has suc­cess­ful­ly com­plet­ed pre-clin­i­­cal eval­u­a­tion of its norovirus vac­cine can­di­date sup­port­ing clin­i­cal test­ing in humans and pub­lished a mile­stone paper in the renowned jour­nal “Vac­cine”.   Norovirus­es are respon­si­ble for approx­i­mate­ly 20% of all cas­es of acute… Read more »

Halle (Saale), Octo­ber 2, 2020. Icon Genet­ics GmbH, a whol­ly owned sub­sidiary of Den­ka Co. Ltd, Tokyo, Japan, has ini­ti­at­ed a Phase I clin­i­cal study of its norovirus vac­cine can­di­date in August, 2020 and now suc­cess­ful­ly final­ized dos­ing of the first of two cohorts. The tri­al is a sin­­gle-cen­ter, ran­dom­ized, dou­ble-blind, con­trolled study that has… Read more »

Sep­tem­ber　23, 2020 Den­ka Com­pa­ny Lim­it­ed Den­ka Com­pa­ny Lim­it­ed (head­quar­ters: Chuo-ku, Tokyo; pres­i­dent: Man­abu Yamamo­to; here­inafter, “Den­ka”) announces that Icon Genet­ics GmbH (head­quar­ters: Halle, Sach­sen-Anhalt, Ger­many; CEO: Kazuyu­ki Hiru­ta, here­inafter, ”Icon Genet­ics”, web­site: www.icongenetics.com ), a group com­pa­ny of Den­ka, began a Phase I study for clin­i­cal devel­op­ment of a norovirus vac­cine in Bel­gium.   The… Read more »

Con­cep­tu­al image of the new R&D facil­i­ty   Den­ka Com­pa­ny Lim­it­ed (head­quar­ters: Chuo-ku, Tokyo; pres­i­dent: Man­abu Yamamo­to; here­inafter, “Den­ka”) announces that Icon Genet­ics GmbH (here­inafter, ”Icon Genet­ics”), a ful­ly owned sub­sidiary of Den­ka, con­clud­ed a land pur­chase agree­ment with the city of Halle, Sach­sen-Anhalt in Ger­many on March 11, 2020. The land will be used… Read more »

Den­ka Com­pa­ny Lim­it­ed (head­quar­ters: Chuo-ku, Tokyo; pres­i­dent: Man­abu Yamamo­to; here­inafter “Den­ka”) here­by announces that on August 21, 2017 it had com­plet­ed the process of acquir­ing 100% of the shares of Icon Genet­ics GmbH (head­quar­ters: Halle, Sach­sen-Anhalt, Ger­many; CEO: Kazuyu­ki Hiru­ta; here­inafter “Icon”). As pre­vi­ous­ly announced on August 7, 2015 via a press release titled “Announce­ment… Read more »

DENKI KAGAKU KOGYO KABUSHIKI KAISHA (Head­quar­tered at: Chuo-ku, Tokyo; Shin­suke Yoshi­ta­ka, Pres­i­dent & CEO, here­inafter ”Den­ka”) is pleased to announce that, it has agreed and entered into a share trans­fer agree­ment on August 6, 2015 with Nomad Bio­science GmbH (Head­quar­tered at: Munich, Ger­many; Prof. Dr. Yuri Gle­ba, CEO, here­inafter ”Nomad”) regard­ing its acqui­si­tion (the ”Acqui­si­tion”)… Read more »